Teleflex Inc. 10-Q Summary: Quarter Ended September 24, 2006
Business Context and Reporting Period
This report covers the quarterly period ended September 24, 2006, and the nine-month period ended on the same date. Teleflex Inc. is a diversified industrial company specializing in specialty-engineered products for commercial, medical, and aerospace industries. The company operates through three segments: Commercial, Medical, and Aerospace.
Key Financial Metrics
| Metric | Three Months Ended Sep 24, 2006 | Nine Months Ended Sep 24, 2006 |
|---|---|---|
| Revenues | $639.1 million | $1,953.9 million |
| Gross Profit | $185.1 million (29.0% margin) | $571.3 million (29.2% margin) |
| Net Income | $36.0 million | $101.7 million |
| Diluted EPS | $0.91 | $2.53 |
| Operating Cash Flow | N/A | $213.7 million |
| Total Debt | $545.3 million | $545.3 million |
| Cash and Equivalents | $202.4 million | $202.4 million |
| Net Debt to Total Capital | 23% | 23% |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 9% in the quarter and 5% for the nine-month period compared to 2005. Core growth (excluding currency and acquisitions) was 6% for the quarter and 5% for the nine months.
- Profitability: Net income rose 7% in the quarter to $36.0 million. Operating profit increased 13% in the quarter, driven by cost and productivity improvements.
- Segment Performance:
- Aerospace: Strongest performer with 17% revenue growth in the quarter and 75% operating profit growth for the nine months.
- Medical: Revenue up 6% in the quarter; operating profit up 14% in the quarter but down 3% for the nine months due to restructuring and IT implementation costs.
- Commercial: Revenue up 7% in the quarter; operating profit surged 60% in the quarter due to operational efficiencies.
- Restructuring: Total restructuring and impairment charges were $3.3 million for the quarter and $16.2 million for the nine months, down from $5.8 million and $19.7 million in the prior year periods.
- Accounting Changes: Adoption of SFAS No. 123(R) resulted in $1.8 million of stock-based compensation expense for the quarter and $5.1 million for the nine months.
Guidance, Outlook, and Risks
- Outlook: Management expects core revenue growth to continue, driven by new product development and market share expansion. The company anticipates incurring future restructuring costs of $5.5 million to $7.5 million related to the 2006 program and $2.8 million to $5.0 million related to the 2004 program over the next three quarters.
- Liquidity: The company maintains strong liquidity with $202.4 million in cash. Net debt decreased to $342.9 million, funded by operating cash flows.
- Capital Allocation: The company completed a $140 million stock repurchase program in the first nine months of 2006. The Board extended the authorization for an additional six months in June 2006.
- Risks: Key risks include raw material cost increases, currency exchange rate fluctuations, integration of acquired businesses, and the outcome of ongoing litigation, including a trademark infringement appeal where a $34.8 million jury verdict was previously rejected by a trial judge.
Investor Verification Checklist
- Verify the impact of the new SFAS No. 123(R) stock-based compensation expense on future earnings.
- Monitor the execution of the 2006 and 2004 restructuring programs and the associated future cost estimates.
- Assess the sustainability of the 13% core growth in the Aerospace segment.
- Review the status of the trademark infringement litigation appeal and potential financial exposure.
- Confirm the timeline and cost benefits of the information systems implementation in the Medical segment.